icon-    folder.gif   Conference Reports for NATAP  
 
  AIDS 2022
July 29 - Aug 2
24th Intl AIDS Conference
Back cgrey_arrow_rt.gif
 
 
 
Dolutegravir versus efavirenz-400 as first-line ART in
Cameroon: week 192 data of NAMSAL trial

 
 
  AIDS 2022 July 29- Aug 1 Montreal
 
Mireille Mpoudi-Etame
 
Authors
M. Mpoudi-Etame * (1), T. Tovar Sanchez (2), P. Omgba Bassega (3), J. Olinga (4), R. Pelloquin (2), M. Foalem (4), C. Njonkep (4), E. Mimbe (4), M. Varloteaux (4), M. Tongo (5), N. Lamare (5), M. Peeters (2), J. Reynes (6,2), E. Delaporte (6,2), S. Koulla-Shiro (4), C. Kouanfack (7,8,4), NAMSAL ANRS 12313 study group
Institutions
(1) Military Hospital of Yaounde, Yaounde, Cameroon, (2) TransVIHMI, University of Montpellier-IRD-INSERM, Montpellier, France, (3) District of the Cite Verte Hospital, Yaounde, Cameroon, (4) Cameroon ANRS-site, Yaounde, Cameroon, (5) CREMER, Yaounde, Cameroon, (6) Montpellier University Hospital Center, Montpellier, France, (7) Faculty of Medicine and Pharmaceutical Sciences University of Dschang, Dschang, Cameroon, (8) Yaounde Central Hospital, Yaounde, Cameroon

0801221copy

0801222copy

0801223copy

0801224copy

0801225copy

0801226copy

0801227copy

0801228copy

0801229copy

08012210copy

08012211copy

08012212copy